ICU sedation, delirium & recovery

Sleep quality and quantity determined by polysomnography in mechanically ventilated critically ill patients randomized to dexmedetomidine or placebo

Acta Anaesthesiol ScandPublished Randomised controlled trial

Authors' conclusion

Total sleep time and sleep efficiency were significantly increased, without elimination of REM sleep, in mechanically ventilated ICU patients randomized to dexmedetomidine, when compared to a control PSG recording performed during non-sedation/standard care.

Study context

Population
Mechanically ventilated critically ill ICU patients
Participants
30 consecutive patients
Comparison
Dexmedetomidine vs placebo, each vs own control polysomnography (PSG) recording
  • Dexmedetomidinen = 20
  • Placebon = 10reference
Primary endpoint
Sleep quality, total sleep time (TST), sleep efficiency (SE) and REM sleep by polysomnography (PSG)
Methodological detailsdouble-blinded, placebo-controlled, two parallel groups, Two 16 h PSG recordings per patient on two consecutive nights; randomised after the first recording (control recording)
  • Double-blinded
  • Placebo-controlled
  • Two parallel groups
  • Two 16 h PSG recordings per patient on two consecutive nights; randomised after the first recording (control recording)

Primary result

As reported in the abstract

SE and TST (PSG), change vs control recording

SE increase

37.6% (29.7;45.6) vs 3.7% (−11.4;18.8)

P < 0.001

Dexmedetomidine

Total sleep time (TST) prolongation

271 (210;324) vs 27 (−82;135) min.

P < 0.001

Dexmedetomidine

Secondary outcomes

Delirium, physical activity, RASS score

No significant difference, except for RASS night two

Original publication

Sleep quality and quantity determined by polysomnography in mechanically ventilated critically ill patients randomized to dexmedetomidine or placebo. Acta Anaesthesiol Scand. Published 21 October 2022. doi:10.1111/aas.14154

Composed by AI from the published abstract and checked against it. How Briefs are made →

Get them every week

New studies on this topic in My Week and in your Monday e-mail.

We e-mail you a sign-in link and a code. No password, no spam.